— Researchers to Present New Phase 2 Data Showing Safety and Anti-Leukemic Activity with WU-CART-007 and Additional New Findings for this Investigational, Off-the-Shelf Allogeneic CAR-T Cell Therapy — — Company to Initiate Follow-Up Study in Q4 2024 with WU-CART-007 in Pediatric and Minimal Residual Disease (MRD) Patients — — Will Share New Data for WU-NK-101,... The post Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Pres...
